Who Exports Gliclazide from India — 238 Suppliers Behind a $300.8M Market
India's gliclazide export market is supplied by 238 active exporters who collectively shipped $300.8M across 3,830 shipments. MYLAN LABORATORIES LIMITED leads with a 60.4% market share, followed by PANACEA BIOTEC PHARMA LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED. The top 5 suppliers together control 83.0% of total export value, reflecting a concentrated market structure.
Top Gliclazide Exporters from India — Ranked by Export Value
MYLAN LABORATORIES LIMITED is the leading gliclazide exporter from India, holding a 60.4% share of the $300.8M market across 3,830 shipments from 238 exporters. The top 5 suppliers — MYLAN LABORATORIES LIMITED, PANACEA BIOTEC PHARMA LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, MICRO LABS LIMITED, IPCA LABORATORIES LIMITED — collectively control 83.0% of total export value, indicating a highly concentrated market. Individual shares are: MYLAN LABORATORIES LIMITED (60.4%), PANACEA BIOTEC PHARMA LIMITED (12.6%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (5.0%), MICRO LABS LIMITED (2.5%), IPCA LABORATORIES LIMITED (2.4%).
Top Gliclazide Exporters from India
Ranked by export value · 238 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED GLICLAZIDE TABLETS 80 MGGLICLAZIDE MODIFIED RELEASE TABLETS 30 MGMYLAN GLICLAZIDE MR 30MG TAB 100BT PACKS22680 | $181.6M | 7 | 60.4% |
| 2 | PANACEA BIOTEC PHARMA LIMITED GLIZYM M TABLETS B/N.18423023 TOGLIZYM M TABLETS B/N.18423026 TOGLIZID M TABLETS B/N.01823003 M/ | $37.9M | 5 | 12.6% |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED MYLAN GLICLAZIDE MR 30MG TAB 100BT PACKS22680AZUKON MR TABLET ( GLICLAZIDE MODIFIED RGLICLAZIDE SUN TAB 30MG 20X50BBR PA | $15.1M | 11 | 5.0% |
| 4 | MICRO LABS LIMITED GLIZYM M TABLETS B/N.18423023 TOGLIZYM M TABLETS B/N.18423026 TOHARMLESS MEDICINES : GLYCINORM 80MG TABLETS ] [PACK:3X10'S] | $7.6M | 17 | 2.5% |
| 5 | IPCA LABORATORIES LIMITED GLIZYM M TABLETS B/N.18423023 TOGLIZYM M TABLETS B/N.18423026 TOHARMLESS MEDICINES : GLYCINORM 80MG TABLETS ] [PACK:3X10'S] | $7.3M | 18 | 2.4% |
| 6 | TORRENT PHARMACEUTICALS LTD AZUKON MR TABLET ( GLICLAZIDE MODIFIED RGLICLAZIDE SUN TAB 30MG 20X50BBR PA63619 PACKS OF GLICLAZIDE MODIFIED RELEA | $6.1M | 3 | 2.0% |
| 7 | LUPIN LIMITED GLICLAZIDE MR TAB 60MG 30 SANDOZ FRANCEGLICLAZIDE 40MG TABLETS 28'SGLICLAZIDE 80MG TABLETS 2X14S | $4.9M | 8 | 1.6% |
| 8 | MEDREICH LIMITED MYLAN GLICLAZIDE MR 30MG TAB 100BT PACKS22680MINT GLICLAZIDE MR 30MG TABLETS- PACK SIGLICLAZIDE 40MG TABLETS 28'S | $3.6M | 2 | 1.2% |
| 9 | STALLION LABORATORIES PVT LTD GLIZID M TABLETS B/N.01823003 M/GLICLAZIDE 30 MG MODIFIED RELEASE TABLETMELANOV MR 60 ( (GLICLAZIDE 60MG TABLETS | $2.7M | 5 | 0.9% |
| 10 | BAL PHARMA LIMITED GLICLAZIDE 30 MG MODIFIED RELEASE TABLET63619 PACKS OF GLICLAZIDE MODIFIED RELEAGLICLAZIDE MR TAB 60MG 30 SANDOZ FRANCE | $2.6M | 17 | 0.9% |
| 11 | TORRENT PHARMACEUTICALS LIMITED AZUKON MR TABLET ( GLICLAZIDE MODIFIED RGLICLAZIDE SUN TAB 30MG 20X50BBR PA63619 PACKS OF GLICLAZIDE MODIFIED RELEA | $2.5M | 2 | 0.8% |
| 12 | CENTAUR PHARMACEUTICALS PRIVATE LIMITED MYLAN GLICLAZIDE MR 30MG TAB 100BT PACKS22680GLICLAZIDE MR TAB 60MG 30 SANDOZ FRANCEMINT GLICLAZIDE MR 30MG TABLETS- PACK SI | $2.4M | 9 | 0.8% |
| 13 | INVENTIA HEALTHCARE LIMITED GLIZYM M TABLETS B/N.18423023 TOGLIZYM M TABLETS B/N.18423026 TOGLIZID M TABLETS B/N.01823003 M/ | $2.0M | 6 | 0.7% |
| 14 | ALKEM LABORATORIES LIMITED | $2.0M | 2 | 0.7% |
| 15 | WALLACE PHARMACEUTICALS PRIVATE LIMITED 63619 PACKS OF GLICLAZIDE MODIFIED RELEAGLITROL CR 60 (GLICLAZIDE CONTROLLED REL | $1.6M | 1 | 0.5% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Gliclazide exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Micro Labs Limited | Not Listed | Yes, inspected Augus | Yes | Not verified | WHO-GMP inspections conducted in 2024 and 2025; EU GMP compliant. |
| Mylan Laboratories Limited | Not Listed | Yes, inspected April | Yes | Not verified | WHO-GMP inspection conducted in 2025; EU GMP compliant. |
| Sun Pharmaceutical Industries Limited | Not Listed | Not Listed | Yes | Not verified | EU GMP compliant. |
| Panacea Biotec Pharma Limited | Not Listed | Not Listed | Yes | Not verified | EU GMP compliant. |
| Unichem Laboratories | Not Listed | Not Listed | Yes | Not verified | EU GMP compliant. |
| Lincoln Pharmaceuticals | Not Listed | Not Listed | Yes | Not verified | EU GMP compliant. |
TransData Nexus reviewed the regulatory standing of 6 leading Gliclazide exporters from India. 0 hold US FDA facility approvals, 2 maintain WHO-GMP certification, and 6 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Gliclazide sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts over 800 pharmaceutical companies, including industry leaders such as Dr. Reddy’s Laboratories, Aurobindo Pharma, and Divi’s Laboratories. Hyderabad's Genome Valley, India's first biotech cluster, provides advanced R&D infrastructure and a skilled talent pool, making it a prime location for API manufacturing.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and is home to major companies like Zydus Cadila, Intas Pharmaceuticals, and Torrent Pharmaceuticals. The region's robust infrastructure, including well-developed ports and transportation networks, supports efficient manufacturing and distribution of pharmaceutical products.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for India's pharmaceutical industry. With 929 pharmaceutical units, Maharashtra is a significant contributor to the sector. The region's proximity to major ports facilitates seamless export operations, making it a strategic location for companies aiming to access international markets.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi and Nalagarh in Himachal Pradesh have emerged as prominent pharmaceutical manufacturing zones, largely due to favorable tax incentives and government policies. Baddi, in particular, is recognized as Asia's largest pharmaceutical hub, housing over 1,000 manufacturing units. The region's strategic location and supportive infrastructure have attracted numerous pharmaceutical companies, contributing significantly to India's pharmaceutical output.
5Sourcing Recommendations
- Diversify Supplier Base: Given that the top five exporters account for 83.0% of Gliclazide shipments, it's advisable to diversify the supplier base to mitigate risks associated with over-reliance on a few sources.
- Engage with Leading Manufacturers: Consider establishing partnerships with top manufacturers such as MYLAN LABORATORIES LIMITED, PANACEA BIOTEC PHARMA LIMITED, and SUN PHARMACEUTICAL INDUSTRIES LIMITED, who collectively contribute a significant portion of Gliclazide exports.
- Leverage Regional Specializations: Utilize the strengths of different pharmaceutical clusters—source APIs from Hyderabad, formulations from Ahmedabad-Vadodara, and leverage Mumbai-Thane-Raigad for export logistics.
- Monitor Regulatory Compliance: Ensure that suppliers adhere to international quality standards and regulatory requirements to maintain product integrity and facilitate smooth export processes.
By strategically engaging with India's diverse pharmaceutical clusters and leading manufacturers, companies can optimize their Gliclazide sourcing strategies to meet global demand effectively.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Gliclazide exporters from India
SUN PHARMACEUTICAL INDUSTRIES LIMITED — Sun Pharma acquires remaining stake in Taro Pharmaceuticals for $347.73 million
In January 2024, Sun Pharma entered into a definitive merger agreement to acquire the remaining stake in Taro Pharmaceuticals for $347.73 million. This acquisition aimed to consolidate Sun Pharma's position in the global pharmaceutical market. - IMPACT: The acquisition is expected to enhance Sun Pharma's production capabilities, potentially increasing Gliclazide exports.
Impact: The acquisition is expected to enhance Sun Pharma's production capabilities, potentially increasing Gliclazide exports.
Common Questions — Gliclazide Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which gliclazide supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MYLAN LABORATORIES LIMITED leads with 133 recorded shipments worth $181.6M. PANACEA BIOTEC PHARMA LIMITED (50 shipments) and SUN PHARMACEUTICAL INDUSTRIES LIMITED (470 shipments) are also established high-volume exporters.
Q How many gliclazide manufacturers are there in India?
India has 238 active gliclazide exporters with a combined export market of $300.8M across 3,830 shipments to 109 countries. The top 5 suppliers hold 83.0% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for gliclazide from India?
Average FOB unit price: $6.75 per unit, ranging from $0.00 to $749.73. Average shipment value: $78.5K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 238 verified Indian exporters of Gliclazide ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,830 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 109 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,830 Verified Shipments
238 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists